Answers are grounded in this paper and cite their sources.
Phase III trial shows nivolumab plus gemcitabine-cisplatin maintains quality of life in patients with advanced urothelial carcinoma, suggesting its standard use.
Adding nivolumab to gemcitabine-cisplatin did not worsen HRQoL compared with gemcitabine-cisplatin alone in the first 16 weeks of therapy. These findings support nivolumab plus gemcitabine-cisplatin as standard first-line therapy for cisplatin-eligible patients with unresectable or metastatic UC.
No takes yet. Share an insight, caveat, or question.
Bedke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: